BROADWOOD CAPITAL INC - Q3 2023 holdings

$1.12 Billion is the total value of BROADWOOD CAPITAL INC's 7 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 28.6% .

 Value Shares↓ Weighting
MNST SellMONSTER BEVERAGE CORP NEW$450,140,446
-15.9%
8,501,236
-8.7%
40.02%
+0.1%
STAA BuySTAAR SURGICAL CO$372,244,677
-19.4%
9,264,427
+5.5%
33.10%
-4.1%
AXON  AXON ENTERPRISE INC$151,244,737
+2.0%
760,0620.0%13.45%
+21.3%
IWM SellISHARES TRrussell 2000 etf$100,034,840
-22.6%
566,000
-18.0%
8.89%
-7.9%
LCTX  LINEAGE CELL THERAPEUTICS INC$41,223,872
-16.3%
34,935,4850.0%3.66%
-0.5%
NewONCOCYTE CORP$7,828,2862,509,066
+100.0%
0.70%
AGE  AGEX THERAPEUTICS INC$2,038,066
-23.9%
2,997,1560.0%0.18%
-9.5%
OCX ExitONCOCYTE CORP$0-50,181,335
-100.0%
-0.86%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-11-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
STAAR SURGICAL CO42Q3 202359.1%
MONSTER BEVERAGE CORP NEW34Q3 202349.7%
ISHARES TR33Q3 202314.8%
ONCOCYTE CORPORATION31Q2 20234.6%
BIOTIME INC25Q2 201917.8%
AXON ENTERPRISE INC24Q3 202313.4%
AGEX THERAPEUTICS INC20Q3 20231.5%
LINEAGE CELL THERAPEUTICS INC17Q3 20235.1%
ASTERIAS BIOTHERAPEUTICS INC16Q4 20182.9%
CYNOSURE INC15Q4 201610.4%

View BROADWOOD CAPITAL INC's complete holdings history.

Latest filings
TypeFiled
42024-04-15
13F-HR2024-02-14
42024-02-08
42024-01-10
42024-01-05
42023-11-30
13F-HR2023-11-14
42023-11-14
42023-11-09
42023-11-06

View BROADWOOD CAPITAL INC's complete filings history.

Compare quarters

Export BROADWOOD CAPITAL INC's holdings